Fezolinetant (Veozah) vs HRT
NK3 receptor antagonist; non-hormonal option for vasomotor symptoms only.
Head to head
We compare mechanism, efficacy data, side-effect profile, and cost.
What we prescribe
First-line choice based on your history, risk factors, and goals.
Bottom line
Individualized care wins. We match the option to your history and preferences.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-07-01. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.